Journal of Modern OncologyJournal of Modern OncologyСовременная онкология1815-14341815-1442LLC Obyedinennaya Redaktsiya26943ArticlesСтатьиResearch ArticleModern treatment possibilities of hormone receptor-positive advanced breast cancer in postmenopausal womenСовременные возможности лечения распространенного гормонозависимого рака молочной‌‌‌‌ железы у пациенток в постменопаузеJackischChristianЯкишКристиан

проф.

Llombart-CussacAntonioЛомбарт-КуссакАнтонио

проф.

Центр по изучению рака молочной железы, клиника Оффенбах, ГерманияУниверситетский госпиталь Арнау Де Виланова, Валенсия, Испания15092014163VOL 16, NO3 (2014)ТОМ 16, №3 (2014)162109042020Copyright ©; 2014, Consilium MedicumCopyright ©; 2014, ООО "Консилиум Медикум"2014Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc/4.0https://modernonco.orscience.ru/1815-1434/article/view/26943

Breast cancer (BC) is the most common cancer in women in the world. HER2-negative hormone receptor-positive BC is present in 70% of all cases of BC. A key role in the treatment of this type of BC plays an endocrine therapy, effective at disease progression as well. This article presents and discusses data on modern treatment options of HER2-negative hormone receptor-positive advanced BC, including combined endocrine and targeted therapy with mTOR inhibitor everolimus.

Рак молочной железы (РМЖ) - наиболее распространенное онкологическое заболевание у женщин в мире. гормонозависимый HER2-негативный РМЖ встречается в 70% всех случаев РМЖ. ключевую роль в лечении данного типа РМЖ играет эндокринная терапия, эффективная и при прогрессировании заболевания. в данном обзоре приводятся и обсуждаются современные возможности лечения гормонозависимого HER2-распространенного РМЖ, в том числе комбинации эндокринной и таргетной терапии с включением ингибитора mTOR эверолимуса.

hormone receptor-positive advanced breast cancermTOR inhibitoreverolimusгормонозависимый распространенный рак молочной железыингибитор mTORэверолимусGLOBOCAN 2012. Cancer Incidence, mortality and prevalence world - wide 2012 estimates; http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspxCardoso F, Harbeck N, Fallowfield L et al. Locally recurrent or metastatic breast cancer. ESMO Clinical Practice Guidelines for diagnosis, treatment and follow - up. Ann Oncol 2012; 23 (Suppl. 7): vii11-9.AGO Breast Committee. Diagnosis and treatment of patients with primary and metastatic breast cancer. Recommendations 2013; http://www.ago-online.deCardoso F, Costa A, Norton L et al. First International consensus guidelines for advanced breast cancer (ABC 1). Breast 2012; 21 (3): 242-52.NCCN Clinical Practice Guidelines. Breast Cancer 2012; 3.Lemieux J, Goodwin P.J, Bordeleau L.J, Lauzier S et al. Quality - of - life measurement in randomized clinical trials in breast cancer: an updated systematic review (2001-2009). J Natl Cancer Inst 2011; 103 (3): 178-231.Kennecke H.F, Ellard S, O’Reilly S, Gelmon .KA. New guidelines for treatment of early hormone - positive breast cancer with tamoxifen and aromatase inhibitors. BC Med J 2006; 48: 121-6.NCCN Clinical Practice Guidelines. Breast Cancer 2012; 3.Cardoso F, Fallowfield L, Costa A et al. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow - up. Ann Oncol 2011; 22 (Suppl. 6): vi25-30.Thong M.S.Y, Mols F, Coeberghet J.W.W et al. The impact of disease progression on perceived health status and quality of life of long - term cancer survivors. J Cancer Surv 2009; 3 (3): 164-73.Johnston S.R, Saccani-Jotti G, Smith I.E et al. Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen - resistant human breast cancer. Cancer Res 1995; 55 (15): 3331-8.Robertson J.F, Willsher P.C, Cheung K.L, Blamey R.W. The clinical relevance of static disease (no change) category for 6 months on endocrine therapy in patients with breast cancer. Eur J Cancer 1997; 33 (11): 1774-9.Gutierrez M.C, Detre S, Johnston S et al. Molecular changes in tamoxifen - resistant breast cancer: Relationship between estrogen receptor, HER-2, and p38 mitogen - activated protein kinase. J Clin Oncol 2005; 23 (11): 2469-76.Beatson G.T. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 1896; 2: 104-7.Beatson G.T. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 1896; 2: 162-5.Cohen M.H, Hirschfeld S, Honiget S.F et al. Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene. Oncologist 2001; 6: 4-11; http://www.advancedbreastcancercommunity.org/treatment/drugs.htmhttp://www.advancedbreastcancercommunity.org/treatment/drugs.htmFaslodex. Wilmington, D.E. AstraZeneca Pharmaceuticals LP 2011.Fedele P, Calvani N, Marino A et al. Targeted agents to reverse resistance to endocrine therapy in metastatic breast cancer: where are we now and where are we going? Crit Rev Oncol Hematol 2012; 84 (2): 243-51.Osborne C.K, Schiff R. Mechanisms of endocrine resistance in breast cancer. Ann Rev Med 2011; 62: 233-47.Yamnik R.L, Digilova A, Davis D.C et al. S6 kinase 1 regulates estrogen receptor - а in control of breast cancer cell proliferation. J Biol Chem 2009; 284: 6361-9.Wander S.A, Hennessy B.T, Slingerland J.M. Next - generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. J Clin Invest 2011; 121: 1231-41.Tanaka C, O’Reilly T, Kovarik J.M et al. Identifying optimal biologic doses of Everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. J Clin Oncol 2008; 26: 1596-602.O’Reilly T, Vaxelaire J, Muller M et al. In vivo activity of RAD001, an orally active rapamycin derivative, in experimental tumor models. Proc Am Assoc Cancer Res 2002; 43: 71. Abstr. 359.Stoica G.E, Franke T.F, Wellstein A et al. Estradiol rapidly activates Akt via the ErbB2 signaling pathway. Mol Endocrinol 2003; 17: 818-30.Ellard S, Gelmon K.A, Chia S et al. A randomized phase II study of two different schedules of RAD001C in patients with recurrent/metastatic breast cancer. J Clin Oncol 2007; 25: 141s (Suppl.). Abstr. 3513.Crowder R.J et al. PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptorpositive breast cancer. Cancer Res 2009; 69 (9): 3955-62.Yue W, Fan P, Wang J et al. Mechanisms of acquired resistance to endocrine therapy in hormone - dependent breast cancer cells. J Steroid Biochem Mol Biol 2007; 106: 102-10.Santen R.J, Song R.X, Zhang Z et al. Adaptive hypersensitivity to estrogen: Mechanisms and clinical relevance to aromatase inhibitor therapy in breast cancer treatment. J Steroid Biochem Mol Biol 2005; 95: 155-65.Bachelot T, Bourgier C, Cropet et al. TAMRAD: A GINECO Randomized Phase II Trial of Everolimus in Combination with Tamoxifen Versus Tamoxifen Alone in Patients (pts) with Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer (MBC) with Prior Exposure to Aromatase Inhibitors (AI). Cancer Res 2010; 70 (Suppl. 24). Abstr. S1-6; http://cancer-res.aacrjournals.org/cgi/content/meeting_abstract/70/24.../S1-6Bachelot T, Bourgier C, Cropet C et al. Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study. JCO 2012; 2718-24.Piccart M, Baselga J, Noguchi S et al. Final progression - free survival analysis of BOLERO-2: a phase III trial of everolimus for postmenopausal women with advanced breast cancer. Presented at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium 2012. San Antonio, TX. Poster P6-04-02.Baselga J, Campone M, Piccartet M et al. Everolimus in postmenopausal hormone - receptor - positive advanced breast cancer. N Engl J Med 2012; 366 (6): 520-9.Yardley D.A, Noguchi S, Pritchard K.I et al. Everolimus Plus Exemestane in Postmenopausal Patients with HR(+) Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis. Adv Ther 2013; 30 (10): 870-84.Gnant M, Baselga J, Rugo H.S et al. Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2. J Natl Cancer Inst 2013; 105 (9): 654-63; http://10.1093/jnci/djt026Dignam J.J, Kocherginsky M.N. Choice and interpretation of statistical tests used when competing risks are present. J Clin Oncol 2008; 26 (24): 4027-34.Kim H.T. Cumulative incidence in competing risks data and competing risks regression analysis. Clin Cancer Res 2007; 13 (2 Pt. 1): 559-65.Glantschnig H, Fisher J.E, Wesolowski G et al. M-CSF, TNF-a and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase. Cell Death Differ 2003; 10 (10): 1165-77.Piccart M, Hortobagy, G.N, Campone M et al. Everolimus plus exemestane for hormone receptor - positive (HR+), human epidermal growth factor receptor-2-negative (HER-) advanced breast cancer (BC): overall survival results from BOLERO-2. Presented at the 9th European Breast Cancer Conference (EBCC-9), 19-21 March 2014. Glasgow, Scotland. Abstr. 1LBA.Burris H, Lebrun F, Rugo H.S et al. Health - related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial. Cancer 2013; 119 (10): 1908-15.Campone M, Beck J.T, Gnant M et al. Health - related quality of life and disease symptoms in postmenopausal women with HR+, HER2-advanced breast cancer treated with everolimus plus exemestane vs. exemestane monotherapy. Curr Med Res Opin 2013; 29 (11): 1463-73.National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Breast Cancer 2014; 3.Pritchard K.I, Gelmon K.A, Rayson D et al. Endocrine therapy for postmenopausal women with hormone receptor - positive her2-negative advanced breast cancer after progression or recurrence on nonsteroidal aromatase inhibitor therapy: a Canadian consensus statement. Curr Oncol 2013; 20 (1): 48-61.